Significant association of past parvovirus B19 infection with cytopenia in both adult-onset Still's disease and systemic lupus erythematosus patients

Clinica Chimica Acta

Volumn 413, Issue 9-10, 2012, Pages 855-860

  Chen, Der Yuan ^a,b,c   Chen, Yi Ming ^a,b   Lan, Joung Liang ^a,b,c   Tzang, Bor Show ^b,d   Lin, Chi Chen ^c   Hsu, Tsai Ching ^b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adult onset Still's disease (AOSD); Arthritis; Cytopenia; Human parvovirus B19 (B19); Nonstructural protein 1 (NS1); VP1 unique region protein (VP1u)

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NONSTRUCTURAL PROTEIN 1; SALAZOSULFAPYRIDINE;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; GENETIC RISK; HUMAN; HUMAN PARVOVIRUS B19; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; WESTERN BLOTTING;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, VIRAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; STILL'S DISEASE, ADULT-ONSET; THROMBOCYTOPENIA; YOUNG ADULT;

PARVOVIRUS;

EID: 84862795791     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.027     Document Type: Article

References (48)

1. Corcoran A., Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004, 53:459-475.
2. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med 2004, 350:586-597.
3. Anderson S., Momoeda M., Kawase M., Kajigaya S., Young N.S. Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology 1995, 206:626-632.
4. Modrow S., Dorsch S. Antibody responses in parvovirus B19 infected patients. Pathol Biol 2002, 50:326-331.
5. Zádori Z., Szelei J., Lacoste M.C., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001, 1:291-302.
6. Dorsch S., Liebisch G., Kaufmann B., et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002, 76:2014-2018.
7. Canaan S., Zádori Z., Ghomashchi F., et al. Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem 2004, 279:14502-14508.
8. Lu J., Zhi N., Wong S., Brown K.F. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006, 193:582-590.
9. Filippone C., Zhi N., Wong S., et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008, 374:444-452.
10. Musiani M., Manaresi E., Gallinella G., Venturoli S., Zuffi E., Zerbini M. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J Med Virol 2000, 60:347-352.
11. von Poblotzki A., Gigler A., Lang B., Wolf H., Modrow S. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol 1995, 76:519-527.
12. Hsu T.C., Tsay G.J. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:152-157.
13. Lehmann H.W., von Landenberg P., Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003, 2:218-223.
14. Chen D.Y., Tzang B.S., Chen Y.M., et al. The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta 2010, 411:1084-1089.
15. Kerr J.R., Cunniffe V.S. Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection. Rheumatology 2000, 39:903-908.
16. Young N. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988, 25:159-172.
17. Ohta A., Yamaguchi M., Kaneoka H., Nagayoshi T., Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987, 14:1139-1146.
18. Yamaguchi M., Ohta A., Tsunematsu T., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
19. Choi J.H., Suh C.H., Lee Y.M., et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003, 30:2422-2427.
20. Chen D.Y., Chen Y.M., Lan J.L., Lin C.C., Chen H.H., Hsieh C.W. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology 2010, 49:2305-2312.
21. Wouters J.M.G.W., van der Veen J., van de Putte L.B.A., de Rooij D.J.R.A.M. Adult Still's disease and viral infection. Ann Rheum Dis 1988, 47:764-767.
22. Izumikawa K., Morinaga Y., Kondo A., et al. Adult Still's disease associated with cytomegalovirus infection. J Infect Chemother 2007, 13:114-117.
23. Bilidi M., Gatfosse M., Barjonet G. Adult onset Still disease associated with acute parvovirus B19 infection in pregnancy. Ann Med Int 1996, 147:518-519.
24. Longo G., Luppi M., Bertesi M., et al. Still's disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection. Clin Infect Dis 1998, 26:994-995.
25. Pouchot J., Quakil H., Debin M.L., et al. Adult Still's disease associated with acute human parvovirus B19 infection. Lancet 1993, 341:1280-1281.
26. Weis P.J., DeMarco P.J., Pischel K.D. Can parvovirus B19 infection trigger adult Still's disease? Report of a case controlled with infliximab. J Clin Rheumatol 2001, 7:277-279.
27. Godeau B., Palazzo E., Morinet F., et al. Is Still's disease associated with parvovirus B19 infection?. Lancet 1994, 59:59-60.
28. Pavlovic M., Kats A., Cavallo M., et al. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010, 19:783-792.
29. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997, 40:1725.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
31. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76:4350-4354.
32. Gallinella G., Zuffi E., Gentilomi G., et al. Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases. J Med Virol 2003, 71:135-139.
33. Cohen B.J., Buckley M.M. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988, 25:151-153.
34. Courouce A.M., Ferchal F., Morinet F., et al. Human parvovirus infection in France. Lancet 1984, 8369:160.
35. Lin K.H., You S.L., Chen C.J., et al. Seroepidemiology of human parvovirus B19 in Taiwan. J Med Virol 1999, 57:169-173.
36. Chen Y.S., Chou P.H., Li S.N., et al. Parvovirus B19 infection in patients with rheumatoid arthritis. J Rheumatol 2006, 33:887-891.
37. Coffernils M., Soupart A., Pradier O., Feremans W., Neve P., Decaux G. Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 1992, 19:1425-1427.
38. Mortimer P.P., Humphries P.K., Moore J.G., Purcell R.H., Young N.S. A human parvovirus-like virus inhibits hematopoietic colony formation in vitro. Nature 1983, 302:426-429.
39. Yoto Y., Kudoh T., Suzuki N., Katoh S., Matsunaga Y., Chiba S. Thrombocytopenia induced by parvovirus B19 infections. Eur J Haematol 1993, 50:255-257.
40. Ramos-Casals M., Cervera R., Garcia-Carrasco M., et al. Cytopenia and past human parvovirus B19 infection in patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2000, 29:373-378.
41. Ozawa K., Ayub J., Kajigaya S., Shimada T., Young N. The gene encoding the non-structural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988, 62:2884-2889.
42. Ozawa K., Kurtzman G., Young N. Replication of the B19 parvovirus in human bone marrow cell culture. Science 1986, 233:883-886.
43. Ozawa K., Kurtzman G., Young N. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro. Blood 1987, 70:384-391.
44. Tzang B.S., Lee Y.J., Yang T.P., et al. Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naïve mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2007, 382:31-36.
45. Tsai C.C., Tzang B.S., Chiang S.Y., Hsu G.J., Hsu T.C. Increased expression of matrix metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J BioMed Sci 2009, 16:1-9.
46. Jones L.P., Erdman D.D., Anderson L.J. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection. J Infect Dis 1999, 180:500-504.
47. Takahashi Y., Murai C., Shibata S., et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998, 95:8227-8232.
48. Horwitz M.S., Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999, 169:241-253.